These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8321481)

  • 1. Radionuclide therapy of cancer: particle range and therapeutic effectiveness.
    Wheldon TE
    Nucl Med Commun; 1993 Jun; 14(6):408-10. PubMed ID: 8321481
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiolanthanides in nuclear medicine.
    Rösch F; Forssell-Aronsson E
    Met Ions Biol Syst; 2004; 42():77-108. PubMed ID: 15206100
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic Radiometals Beyond
    Müller C; van der Meulen NP; Benešová M; Schibli R
    J Nucl Med; 2017 Sep; 58(Suppl 2):91S-96S. PubMed ID: 28864619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Elgqvist J; Timmermand OV; Larsson E; Strand SE
    Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Future of Radioligand Therapy: α, β, or Both?
    Haberkorn U; Giesel F; Morgenstern A; Kratochwil C
    J Nucl Med; 2017 Jul; 58(7):1017-1018. PubMed ID: 28408527
    [No Abstract]   [Full Text] [Related]  

  • 6. Dosimetric aspects of radiolabeled antibodies for tumor therapy.
    Humm JL
    J Nucl Med; 1986 Sep; 27(9):1490-7. PubMed ID: 3528417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radionuclide-antibody conjugates for single-cell cytotoxicity.
    Mattes MJ
    Cancer; 2002 Feb; 94(4 Suppl):1215-23. PubMed ID: 11877748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and potential therapeutic uses of lanthanide radioisotopes.
    Cutler CS; Smith CJ; Ehrhardt GJ; Tyler TT; Jurisson SS; Deutsch E
    Cancer Biother Radiopharm; 2000 Dec; 15(6):531-45. PubMed ID: 11190486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined molecular targeting for cancer therapy: a new paradigm in need of molecular imaging.
    DeNardo SJ
    J Nucl Med; 2006 Jan; 47(1):4-5. PubMed ID: 16391180
    [No Abstract]   [Full Text] [Related]  

  • 11. Intraoperative beta probe: a device for detecting tissue labeled with positron or electron emitting isotopes during surgery.
    Daghighian F; Mazziotta JC; Hoffman EJ; Shenderov P; Eshaghian B; Siegel S; Phelps ME
    Med Phys; 1994 Jan; 21(1):153-7. PubMed ID: 8164582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
    Aghevlian S; Boyle AJ; Reilly RM
    Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicellular dosimetry for micrometastases: dependence of self-dose versus cross-dose to cell nuclei on type and energy of radiation and subcellular distribution of radionuclides.
    Goddu SM; Rao DV; Howell RW
    J Nucl Med; 1994 Mar; 35(3):521-30. PubMed ID: 8113908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoradiography imaging in targeted alpha therapy with Timepix detector.
    A L Darwish R; Staudacher AH; Bezak E; Brown MP
    Comput Math Methods Med; 2015; 2015():612580. PubMed ID: 25688285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Imagers for Quantitative, Single-particle Digital Autoradiography of Alpha- and Beta-particle Emitters.
    Miller BW
    Semin Nucl Med; 2018 Jul; 48(4):367-376. PubMed ID: 29852946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
    Marcu L; Bezak E; Allen BJ
    Crit Rev Oncol Hematol; 2018 Mar; 123():7-20. PubMed ID: 29482781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Semiconductor detectors for the intracavitary and interstitial radiophosphorus diagnosis of cancer].
    Afanas'eva NP; Eremin VK; Strokan NB; Tarkhin DV
    Med Radiol (Mosk); 1983 Sep; 28(9):62-4. PubMed ID: 6621285
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer.
    Pietersz GA; Kanellos J; Smyth MJ; Zalcberg J; McKenzie IF
    Immunol Cell Biol; 1987 Apr; 65 ( Pt 2)():111-25. PubMed ID: 3301638
    [No Abstract]   [Full Text] [Related]  

  • 19. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (99m)Tc Auger electrons for targeted tumour therapy: a review.
    Tavares AA; Tavares JM
    Int J Radiat Biol; 2010 Apr; 86(4):261-70. PubMed ID: 20353336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.